
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
San Diego-Treatment with the dual neurotransmitter reuptake inhibitor duloxetine (Yentreve) results in durable improvement in symptoms of stress urinary incontinence, according to a study of open-label transition from placebo to active therapy.





